1. Home
  2. RNAZ
  3. RNAZ Forecast

as of 12-08-2025 3:59pm EST

$8.35
$0.26
-3.02%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

Frequently Asked Questions

Learn more about our RNAZ ML prediction model

What parameters are used to train the RNAZ ML model?

Our stocks RNAZ ML model is trained using historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other technical metrics.

How often is the RNAZ ML model updated?

We update our ML model weekly or biweekly (depending on market capitalization) using TensorFlow, typically over the weekend to ensure the most current predictions.

Why might the model accuracy vary?

Our current data provider offers limited historical data, which can impact accuracy. As we continue to gather more data and add additional indicators, we expect the model's accuracy to improve over time.

How can I contribute data to improve accuracy?

We greatly appreciate contributions! Please contact us at info@finquota.com to discuss how you can help improve our models.

Are shorter timeframe predictions available?

Yes, we offer predictions for strategy purposes with shorter intervals including 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes timeframes.

Should I use this for financial decisions?

Our ML model is designed for educational purposes only and should not be used as the sole basis for financial decisions. Always consult with a qualified financial advisor before making any investment decisions.

Share on Social Networks: